A New Treatment for Refractory Autoimmune Hemolytic Anemia: CD19 CAR T-Cell Therapy
In this article
New England Journal of Medicinepublished, on 14 January 2026, a studythat extends the boundaries of CAR T-cell therapy beyond cancer treatment. In patients with autoimmune hemolytic anemia (AIHA) unresponsive to at least three lines of treatment (multirefractory), a single dose of CD19-targeted CAR-T therapy was shown to produce lasting, drug-free recovery. This may herald a new era in treating autoimmune diseases.
Why Does It Matter?
Autoimmune hemolytic anemia (AIHA) is a serious disease in which the body’s own immune system (B cells) attacks and destroys red blood cells. Standard treatments (steroids, rituximab, etc.) generally provide temporary relief, but the risk of relapse is high.
For advanced patients described as ‘multirefractory’ (resistant to multiple treatments), options approach exhaustion. This study provides some of the first substantial evidence that CAR-T technology, which revolutionized cancer treatment, can, by deeply depleting B cells , achieve ‘drug-free complete remission’ (complete cessation of disease) even in these refractory patients.
🔍 Glossary
AIHA (Autoimmune Hemolytic Anemia): A type of anemia in which the immune system destroys the body’s own blood cells.
CAR T Cell: A ‘living drug’ in which T cells taken from the patient are genetically modified in the laboratory and reprogrammed to attack a target (here, B cells carrying CD19).
CD19: A protein found on the surface of B cells (both normal and diseased), serving as the target of CAR-T cells.
Cytokine Release Syndrome (CRS): A common adverse effect of CAR-T therapy that can range from flu-like symptoms (fever, etc.) to organ failure.
1. Study Design and Participants
The study enrolled patients diagnosed with primary AIHA who had failed to respond to at least three different lines of treatment (multirefractory): 11 patients were included (5 from a compassionate-use program and 6 from a Phase 1 trial).
Each patient received a single infusion of CD19 CAR T cells manufactured from their own blood (autologous). The primary aim was to assess safety (adverse effects), and the secondary aim was to assess efficacy (complete response, drug-free interval).
2. Striking Results: 100% Complete Response
Data obtained after a median follow-up of 12.2 months are extremely promising regarding the treatment’s efficacy.
Treatment Response and Timelines
Complete response was defined as the disappearance of symptoms, an increase in hemoglobin levels and normalization of hemolysis (blood cell destruction) markers. Examination of B-cell reconstitution after treatment showed a predominance of ‘naive’ (inexperienced/new) B cells, indicating successful elimination of the disease-causing B cells with ‘harmful memory’.
3. Safety and Adverse Effects
Expected Toxicities
- Cytokine Release Syndrome (CRS): Occurred in 9 of 11 patients, but all cases were mild (Grade 1–2).
- Neurotoxicity (ICANS): Occurred in only 1 patient and was mild (Grade 1).
- Infections: There were 15 infectious episodes in 7 patients, but none was life-threatening (Grade 4 or above).
Original Article
Li R, Pan H, Zhang L, et al. "CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia." N Engl J Med. 2026 Jan 14;394:253-267. DOI: 10.1056/NEJMoa2509820
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.